Drug Topics

APRIL 17, 2024

With an unprecedented number of Americans in need of mental health care, what role should pharmacists play when it comes to screenings?

201

201

Pharmacy Times

APRIL 17, 2024

If approved, the test could provide more timely and accurate diagnosis, hopefully mitigating the impact of Alzheimer disease (AD) on individuals and the community.

FDA 177

FDA 177

Drug Topics

APRIL 17, 2024

Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.

FDA 201

FDA 201

STAT

APRIL 17, 2024

Eli Lilly reported positive results for its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market. The results also pave the way for Zepbound to potentially become the first approved treatment for obstructive sleep apnea, or OSA, a common disorder characterized by breathing interruptions during sleep.

145

145

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

APRIL 17, 2024

The ongoing opioid crisis in the United States shows no signs of slowing down. As trusted community health care professionals, pharmacists must play a key role in fighting it.

201

201

STAT

APRIL 17, 2024

The fight against malaria is a test of human intelligence against mosquitoes — and so far, our minuscule winged enemy is winning. But new results shared this week show substantial improvements in one of the most important tools we have to prevent the life-threatening disease: bed nets. Results shared this week by the New Nets Project, an initiative funded by Unitaid and the Global Fund, highlighted a pair of second-generation bed nets tested in endemic areas between 2019 and 2022.

145

145

STAT

APRIL 17, 2024

A new analysis of health inequities in the United States shows that every state has deep racial and ethnic disparities in the performance of their health care systems. The report released Thursday by the Commonwealth Fund analyzed 25 indicators that track health outcomes, health care access, and quality of care provided for five racial and ethnic groups.

144

144

Pharmacy Times

APRIL 17, 2024

IMPACT CKD, a modeling analysis created by AstraZeneca, includes data about chronic kidney disease across 8 countries, including the United States.

139

139

STAT

APRIL 17, 2024

When my son Conall took his life at age 17, it was devastating to me and our entire family. Conall was a caring, empathetic, and bright young man, but he had also struggled for many years with anxiety and depression. Like many kids his age, much of his life revolved around social media. While I understand that suicide is complex, with many different factors contributing to someone’s risk for it, I know that social media intensified and fueled Conall’s insecurities and ultimately ha

143

143

Fierce Healthcare

APRIL 17, 2024

Though physicians are quickly growing more comfortable with generative AI, the vast majority expect models to be transparent and trained on credible information, a new

138

138

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Fierce Pharma

APRIL 17, 2024

One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis (MS) drug Ocrevus ahead of an FDA decision, the Swiss pharma said. | One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis drug Ocrevus ahead of an FDA decision, the Swiss pharma said.

FDA 133

FDA 133

STAT

APRIL 17, 2024

Federal rules forcing hospitals and insurers to post rates for medical procedures have taken effect, but the data’s so messy that a crop of new startups is rushing in to make a business out of parsing it for whoever is willing to pay. Silicon Valley venture funds Andreessen Horowitz and Yosemite, the cancer-focused fund launched by Steve Jobs’ son Reed Jobs , are backing the small but growing group of companies eager to sift through complex pricing data to help patients and employe

Hospitals 132

Hospitals Insurance 132

Pharmacy Times

APRIL 17, 2024

The product is currently being investigated alongside TLX101 in the IPAX-Linz and IPAX-2 clinical trials, and have previously shown efficacy in the IPAX-1 trial.

FDA 132

FDA 132

STAT

APRIL 17, 2024

Before the Covid-19 pandemic, viral hepatitis killed more people in the United States than all 60 other reportable infectious diseases combined, including HIV, pneumonia, and tuberculosis. Which doesn’t really make sense, since effective vaccines are available for hepatitis A and B, there are successful therapies for hepatitis B, and there’s a treatment that can cure hepatitis C.

Vaccines 130

Vaccines 130

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Fierce Healthcare

APRIL 17, 2024

Health systems across the country face the same pressing problem — rising levels of burnout among physicians. It’s a challenge that’s reaching a crisis point. | A growing number of hospitals and health systems are betting on advancements in AI as part of the cure for what ails physicians. Rush University System for Health is partnering with Suki to trial its AI assistant and Children’s Hospital Los Angeles is rolling out Nabla's Copilot tool.

Hospitals 130

Hospitals 130

STAT

APRIL 17, 2024

Consumer neurotechnology is booming. You can buy a funky-looking headband for $500 on the internet if you want your own personal EEG to track your brain data. But before you click purchase, you might want to check out the device’s privacy policy. These consumer devices are unlikely to include any protections or restrictions around how companies can employ or sell a user’s neural data, according to a new report from the Neurorights Foundation , a nonprofit that advocates for the eth

HIPAA 129

HIPAA 129

pharmaphorum

APRIL 17, 2024

Discover how AI is transforming medical communications and reshaping the future of healthcare. Learn about the latest trends, technologies, and advancements in this rapidly evolving field.

Communication 124

Communication 124

STAT

APRIL 17, 2024

At the J.P. Morgan Healthcare Conference in January, Teladoc CEO Jason Gorevic dismissed the growing chorus of naysayers, expressing confidence in his company’s trajectory and asserting, “I think that we are probably still underappreciated with respect to our market advantage, the financial performance that we’ve demonstrated, as well as the bright outlook we have in terms of our growth potential going forward.

128

128

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Fierce Pharma

APRIL 17, 2024

In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. | In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. Now, two trials have shown that Eli Lilly’s weight loss product Zepbound (tirzepatide) can help patients overcome obstructive sleep apnea (OSA).

119

119

pharmaphorum

APRIL 17, 2024

Learn about the importance of reshoring the UK pharmaceutical supply chain for future resilience. Discover how this strategic move can enhance local production and secure the availability of critical medications.

119

119

Drug Topics

APRIL 17, 2024

Overall, older adults with diabetes faced a 53% higher risk of developing at least 1 functional limitation during the pandemic compared to older adults without diabetes.

112

112

pharmaphorum

APRIL 17, 2024

As Reuters Pharma Europe 2024 comes to a close in Barcelona, pharmaphorum remains on site to live blog the last remaining talks and insights.

119

119

Fierce Pharma

APRIL 17, 2024

After proving the merits of its drug delivery platform last year with the approval of Teva’s long-acting schizophrenia drug Uzedy, France’s Medincell has hooked another big-name partner. | Medincell and AbbVie inked a development and licensing pact to create up to six long-acting injectables, Medincell said Wednesday. Under the deal, Medincell is line to receive an upfront payment of $35 million plus much more in potential development and commercial milestones.

110

110

pharmaphorum

APRIL 17, 2024

The FTC is seeking a $7 million fine on telehealth company Cerebral for violating patients' data privacy and making cancellation difficult.

119

119

Pharmaceutical Commerce

APRIL 17, 2024

A panel uncovers the value in meeting carbon-neutral goals by 2030.

105

105

pharmaphorum

APRIL 17, 2024

Sage Therapeutics has suffered another disappointment after deciding that it will have to drop the Parkinson’s programme for key pipeline drug dalzanemdor after it showed no benefit in a phase 2 trial. The oral positive allosteric modulator (PAM) of the NMDA receptor is being investigated to see if it can counteract mild cognitive impairment in neurodegenerative disorders, and the PRECEDENT trial in Parkinson’s is the first major readout from the drug programme.

115

115

The Checkup by Singlecare

APRIL 17, 2024

Mounjaro (active ingredient tirzepatide) is a brand-name injectable medication approved by the Food and Drug Administration (FDA) to treat Type 2 diabetes mellitus (the most common form of diabetes) in adults. The single-dose injectable pen is available in different strengths, but a 2.5 mg dose is recommended to start. Like other GLP-1 receptor agonists , it works by mimicking natural hormones to regulate blood sugar levels , enhance insulin production, suppress appetite, and slow gastric empty

Dosage 105

Dosage FDA Labelling 105

pharmaphorum

APRIL 17, 2024

Drug shortages fuelled by Brexit are now the 'new normal' in the UK and worsened in 2023, says Nuffield Trust report.

111

111

Pharmaceutical Commerce

APRIL 17, 2024

The latest news for pharma industry insiders.

105

105

pharmaphorum

APRIL 17, 2024

GSK reveals data from EAGLE-1 trial of novel antibiotic gepotidacin for gonorrhoea, amid growing resistance to existing antibiotics.

110

110

STAT

APRIL 17, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. So the GLP-1s strike again: Eli Lilly’s Zepbound seems to work in obstructive sleep apnea as well. Beyond that, we see up close how Amylyx’s ALS drug — which it is pulling from the market — really didn’t differ much from placebo, and see more market and investment potential for psychedelics.

104

104

pharmaphorum

APRIL 17, 2024

MaaT Pharma's microbiota therapy MaaT013 shows survival benefit in acute GvHD in an early access programme, boding well for an ongoing phase 3 trial.

105

105

STAT

APRIL 17, 2024

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is maple bourbon.

Insurance Coverage 103

Insurance Coverage FDA Insurance 103